- Home
- NAAS vs COCH Comparison
NAAS vs COCH Comparison
Compare NAAS & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NAAS | COCH |
|---|---|---|
| Founded | 2019 | 1995 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Blank Checks |
| Sector | Consumer Discretionary | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.8M | 49.9M |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NAAS | COCH |
|---|---|---|
| Price | $2.59 | $0.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $2.17 |
| AVG Volume (30 Days) | 15.3K | ★ 74.0K |
| Earning Date | 11-29-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.45 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $241,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $17.14 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 7.11 |
| 52 Week Low | $1.80 | $0.36 |
| 52 Week High | $4.10 | $0.95 |
Technical Indicators
Market Signals| Indicator | NAAS | COCH |
|---|---|---|
| Relative Strength Index (RSI) | 26.42 | 37.96 |
| Support Level | $2.23 | $0.36 |
| Resistance Level | $2.70 | $0.75 |
| Average True Range (ATR) | 0.16 | 0.04 |
| MACD | -0.05 | -0.00 |
| Stochastic Oscillator | 10.99 | 48.43 |
Price Performance
Historical ComparisonAbout NAAS NaaS Technology Inc.
Naas Technology Inc is an electric vehicle charging service provider in China, whose vision is to power the world with carbon-neutral energy. It offers an integrated set of online solutions to charging station operators, a wide range of offline services that simplify the daily operations of charging station operators, and non-charging services such as food and beverage services to station operators.
About COCH Envoy Medical Inc.
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.